EASL Congress 2026: Selected coverage on viral hepatitis

The European Association for the Study of the Liver (EASL) Congress was held in Barcelona, Spain on 27-30 May 2026. Check out the official website of the Congress.

Here is selected coverage on viral hepatitis:

• AJMC: Where the field of viral hepatitis stands and where it’s heading

Hepatitis B:

• GSK: Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B /press release/

— SEE ALSO: aidsmap: Bepirovirsen leads to functional cure in one fifth of people with long-term hepatitis B

— SEE ALSO: CIDRAP: Phase 3 trials of novel drug show functional cure in 20% of chronic hepatitis B patients

— SEE ALSO: Healio: Bepirovirsen demonstrates 20% functional cure rate in chronic hepatitis B

— SEE ALSO: AJMC: Bepirovirsen achieves clinically meaningful functional cure rates in chronic hepatitis B

• Precision BioSciences announces new and late-breaking PBGENE-HBV clinical data from the ELIMINATE-B study at European Association for the Study of the Liver Congress 2026 /press release/
• Tune Therapeutics presents positive Phase 1b/2a proof of concept data on TUNE-401: a first-in-class epigenetic silencer for patients with hepatitis B at EASL 2026 /press release/

— SEE ALSO: AJMC: First clinical evidence of gene editing, epigenetic silencing of HBV cccDNA

• Brii Bio presents late-breaking data from its Phase 2 ENSURE study at EASL Congress 2026, further supporting the potential role of BRII-179 in achieving durable immunological control of HBV /press release/
• Aligos Therapeutics presents positive data at the EASL Congress 2026 /press release/

— SEE ALSO: AJMC: Pevifoscorvir shows strong HBV activity, durable antigen suppression

• AJMC: AHB-137 demonstrates high cure rates, sustained viral suppression in chronic hepatitis B
• AJMC: Peg-IFNα-2b drives HBsAg loss, outperforms NAs in high-risk hep B

Hepatitis D:

• BioPharm International: Vir Biotechnology reports 96-week Phase 2 hepatitis delta data for tobevibart and elebsiran combination
• AJMC: Tobevibart plus elebsiran shows durable viral suppression in chronic HDV at 96 weeks

— SEE ALSO: AJMC: Tobevibart-elebsiran sustains HDV suppression at 96 weeks: Tarik Asselah, MD, PhD

Hepatitis C:

• Atea Pharmaceuticals presents new drug-drug interaction results supporting potential best-in-class profile of the regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus at EASL Congress 2026 /press release/
• European Medical Journal: EASL 2026: Hepatitis C testing barriers delay early treatment